Zydus gets USFDA’s final approval for Fesoterodine Fumarate Extended-Release Tablets

05 Oct 2017 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The sales of Fesoterodine Fumarate Extended-Release Tablets are estimated at $195.5 million, as per IMS Health.

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. Fesoterodine is used to treat an overactive bladder with symptoms of urinary frequency, urgency, and incontinence. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

919.90 -4.45 (-0.48%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×